Which Statements About SLE Are True?
Statements b, d, and e are TRUE; statements a and c are FALSE. SLE arthritis is characteristically non-deforming (unlike rheumatoid arthritis), and while fever can occur in SLE, it is not a frequent presentation as fever of unknown origin.
Detailed Analysis of Each Statement
a) Arthritis is usually deforming - FALSE
SLE arthritis is characteristically non-deforming and non-erosive, which is a key distinguishing feature from rheumatoid arthritis. This is a classic teaching point in rheumatology—while joint pain and synovitis are common in SLE (occurring in up to 90% of patients), the arthritis typically does not cause permanent joint deformities or erosive changes on radiographs. When deformities do occur (Jaccoud's arthropathy), they are reducible and result from ligamentous laxity rather than true erosive disease.
Clinical Pitfall: Don't confuse SLE arthritis with rheumatoid arthritis. The non-deforming nature is diagnostically important and affects long-term prognosis regarding joint function.
b) Non-infectious endocarditis may occur - TRUE
Libman-Sacks endocarditis (LSE) is a well-recognized cardiac manifestation of SLE, characterized by sterile valvular vegetations 1, 2, 3. This non-infectious endocarditis:
- Most commonly affects the mitral and aortic valves
- Can involve multiple valves simultaneously 2
- May present as the initial manifestation of previously undiagnosed SLE 1, 3, 4
- Is strongly associated with antiphospholipid syndrome (APS), whether primary or secondary to SLE 1, 5, 6
- Can cause significant complications including valvular regurgitation, thromboembolic events (particularly stroke), and heart failure 1, 6
Critical Diagnostic Challenge: LSE can mimic infective endocarditis clinically and on imaging 3, 4. A high index of suspicion is essential, particularly in young patients with unexplained valvular disease, recurrent miscarriages, or thromboembolic events. The presence of positive autoimmune serology, antiphospholipid antibodies, and absence of positive blood cultures helps distinguish LSE from infectious endocarditis.
c) It may frequently present as fever of unknown origin - FALSE
While fever can certainly occur in SLE as part of disease activity, SLE does not "frequently" present as fever of unknown origin (FUO). This statement overstates the frequency. SLE more commonly presents with:
- Constitutional symptoms combined with specific organ involvement
- Malar rash, photosensitivity, or other cutaneous manifestations
- Arthritis/arthralgias
- Renal involvement (often asymptomatic initially)
- Hematologic abnormalities
Important Caveat: When SLE patients do present with fever, it's crucial to exclude infection (especially in immunosuppressed patients) before attributing it to lupus activity. The 2010 EULAR guidelines note that significantly elevated CRP (>50 mg/L) in SLE should raise suspicion for superimposed infection rather than lupus activity alone 7.
d) Antibodies with high diagnostic specificity are Anti-Sm and Anti-dsDNA - TRUE
Both anti-Smith (anti-Sm) and anti-dsDNA antibodies have high diagnostic specificity for SLE, though with important nuances 8, 9:
Anti-dsDNA:
- Holds the most prominent position in the EULAR/ACR 2019 classification criteria 8
- High specificity when detected by appropriate methods (particularly CLIFT - Crithidia luciliae immunofluorescence test) 8
- Associated with lupus nephritis and disease activity 8, 7
- Recommended testing strategy: Double-screening with solid-phase assay (SPA) first, followed by CLIFT confirmation 8
Anti-Sm:
- Highly specific for SLE - when present with anti-dsDNA, it is "exclusively detected in SLE" 9
- Predicts certain clinical patterns: patients with anti-Sm alone show more frequent CNS manifestations 9
- When combined with anti-dsDNA, associated with higher rates of renal involvement (92.9%) 9
Critical Understanding: The 2023 expert panel emphasizes that anti-dsDNA is actually a heterogeneous group of antibodies targeting different DNA structures, not a uniform entity 8. This heterogeneity explains inter-assay variability and why different testing methods may yield different results in the same patient.
e) Renal involvement is of particular importance for the prognosis of the disease - TRUE
Lupus nephritis is a major determinant of morbidity, mortality, and long-term prognosis in SLE 8, 10:
- Kidney involvement is a major cause of morbidity and mortality leading to high medical and societal costs 10
- The 2019 EULAR/ERA-EDTA guidelines emphasize that delays in diagnosis and treatment lead to increased organ damage 8, 10
- Renal survival predictors at 5 years include: age, ethnicity, serum creatinine, hypertension, C3 complement levels, and kidney biopsy findings (activity and chronicity indices) 7
- Risk of doubling serum creatinine: 7.4-8.5% at 5 years and 14.3-18.2% at 10 years 7
- Renal relapses are common, occurring in up to 45% of patients with a flare rate of 0.1-0.2 flares/patient/year 7
Management Algorithm for Suspected Lupus Nephritis:
- Kidney biopsy is indispensable when proteinuria ≥0.5 g/24 hours or unexplained GFR decrease 10
- Test for anti-dsDNA, anti-C1q, complement levels (C3/C4), and antiphospholipid antibodies 10
- Immunosuppressive treatment is recommended for:
- Active class III or IV LN (with or without chronicity)
- Class V LN with nephrotic-range proteinuria or proteinuria >1 g/24 hours despite optimal RAAS blockade for ≥3 months 10
Prognostic Significance: The 2023 guidelines note that lupus nephritis with or without anti-dsDNA may reflect different pathophysiological situations and different syndromes 8. This underscores why renal involvement requires specialized monitoring and aggressive treatment to preserve long-term kidney function and patient survival.